<SEC-DOCUMENT>0000939767-25-000127.txt : 20251104
<SEC-HEADER>0000939767-25-000127.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104162510
ACCESSION NUMBER:		0000939767-25-000127
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		251449528

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel-20251104.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:58ca7a64-f6c5-4884-ae81-544de3b20dd3,g:32284b26-19fc-4127-ab96-9bdd2ce3e58d,d:05b049660c26401fbd2f3a1ce35f5faa-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20251104</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20251104.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-04</xbrli:startDate><xbrli:endDate>2025-11-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i05b049660c26401fbd2f3a1ce35f5faa_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:108.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 04, 2025</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;vertical-align:middle"><div style="text-align:center"><img src="exel-20251104_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px" id="i-1"/></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">EXELIXIS, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:38.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30235</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-3257395</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Alameda</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">837-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:39.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock $0.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i05b049660c26401fbd2f3a1ce35f5faa_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;4, 2025, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended October&#160;3, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01. Other Events.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2025, Exelixis announced that the Board of Directors authorized the repurchase of up to $750 million of its common stock before December 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference only with respect to the discussion in the section titled &#8220;Stock Repurchase Program.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.  Financial Statements and Exhibits.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20250930exhibit991.htm">Press Release issued November 4, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i05b049660c26401fbd2f3a1ce35f5faa_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey J. Hessekiel</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:100%">Jeffrey J. Hessekiel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and General Counsel <br/></span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel20250930exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2b2b40c0a1734efb8a85df27ac801c6e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:9pt"><img alt="image.jpg" src="image.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:175px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chris Senner</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7240</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">csenner&#64;exelixis.com</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Susan Hubbard</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">EVP, Public Affairs &#38; Investor Relations</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-8194</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">shubbard&#64;exelixis.com</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Announces Third</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Quarter 2025</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results and Provides Corporate Update</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">-</font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">-</font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Announced Additional Stock Repurchase Program for up to $750 million by the End of 2026 -</font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Conference Call and Webcast Today at 5&#58;00 PM Eastern Time -</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">ALAMEDA, Calif.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">November&#160;4, 2025</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> - Exelixis, Inc. (Nasdaq&#58; EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on critical strategic priorities across the research &#38; development portfolio,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. &#8220;The cabozantinib franchise continued to outperform with sustained growth in renal cell carcinoma and neuroendocrine tumors, where CABOMETYX&#174; built on its position as the leading oral therapy for new patient market share in second-line and later settings. In October, we presented the detailed positive results from the STELLAR-303 pivotal trial evaluating zanzalintinib in combination with atezolizumab in advanced colorectal cancer at the 2025 European Society for Medical Oncology Congress, along with a simultaneous publication in </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The Lancet.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> Based on these results, we intend to complete the submission of our first new drug application for zanzalintinib in the U.S. before year-end. We also made strong progress across the range of ongoing and planned zanzalintinib pivotal trials, as well as the four ongoing phase 1 clinical studies from our early-stage pipeline where we&#8217;re looking to profile and move the most promising candidates into full development. I want to thank the entire Exelixis team for their collective efforts and unwavering commitment as we work toward our goals of improving standards of care and helping more patients with cancer.&#34; </font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.192%"><tr><td style="width:1.0%"></td><td style="width:56.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Page 2 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">November&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Third Quarter 2025</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Results</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Total revenues </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September&#160;30, 2025 were $597.8&#160;million, as compared to $539.5&#160;million for the comparable period in 2024. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues for the quarter ended September&#160;30, 2025 included net product revenues of $542.9 million, as compared to $478.1&#160;million for the comparable period in 2024. The increase in net product revenues was primarily due to an increase in sales volume.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">Collaboration revenues, composed of license revenues and collaboration services revenues, were $54.8&#160;million for the quarter ended September&#160;30, 2025, as compared to $61.5&#160;million for the comparable period in 2024. The decrease in collaboration revenues was primarily related to lower milestone-related revenues recognized in the quarter and lower development cost reimbursements earned, partially offset by higher royalty revenues for the sales of cabozantinib outside the U.S. generated by Exelixis&#8217; collaboration partner Ipsen Pharma SAS (Ipsen).</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended September&#160;30, 2025 were $199.2&#160;million, as compared to $222.6&#160;million for the comparable period in 2024. The decrease in research and development expenses was primarily related to decreases in clinical trial costs and license and other collaboration costs.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended September&#160;30, 2025 were $123.7 million, as compared to $111.8 million for the comparable period in 2024. The increase in selling, general and administrative expenses was primarily related to increases in stock-based compensation and consulting and outside services.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Provision for income taxes </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September&#160;30, 2025 was $58.8 million, as compared to $36.8&#160;million for the comparable period in 2024.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Restructuring expenses </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September&#160;30, 2025 were $19.8 million. The restructuring expenses primarily consist of severance and employee-related costs. In August 2025, Exelixis&#8217; Board of Directors authorized a corporate reorganization plan (the Plan) to reorganize the Company&#8217;s workforce and close the office located in King of Prussia, Pennsylvania. In connection with the Plan, the Company estimates that it will incur aggregate charges of approximately $20.5 million. The majority of these costs were incurred in the third quarter of 2025. The Plan was implemented in the third quarter of fiscal year 2025 and is expected to be substantially completed by the end of fiscal year 2025. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Impairment of long-lived assets </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September 30, 2024 of $51.7 million was related to the non-cash asset impairment charge to certain of Exelixis&#8217; leased facilities.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP net income</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended September&#160;30, 2025 was $193.6&#160;million, or $0.72 per share, basic and $0.69 per share, diluted, as compared to GAAP net income of $118.0&#160;million, or $0.41 per share, basic and $0.40 per share, diluted, for the comparable period in 2024. GAAP net income per share for the quarter ended September&#160;30, 2025 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended September&#160;30, 2025, as compared to the comparable period in 2024, as a result of the stock repurchase programs.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP net income </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September&#160;30, 2025 was $217.9&#160;million, or $0.81 per share, basic and $0.78 per share, diluted, as compared to non-GAAP net income of $135.7&#160;million, or $0.47&#160;per share, basic and diluted, for the comparable period in 2024. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.192%"><tr><td style="width:1.0%"></td><td style="width:56.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Page 3 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">November&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">To supplement Exelixis&#8217; financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation, adjusted for the related income tax effect for all periods presented.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Exelixis&#8217; results from period to period, and to identify operating trends in Exelixis&#8217; business. Exelixis has excluded stock-based compensation, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis&#8217; business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">2025 Financial Guidance</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is providing the following updated financial guidance for fiscal year 2025. </font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Current Guidance</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(provided on November 4, 2025)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Previous Guidance</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(provided on May 13, 2025)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$2.30 billion - $2.35 billion</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$2.25 billion - $2.35 billion</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$2.10 billion - $2.15 billion</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$2.05 billion - $2.15 billion</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#126;4% of net product revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">4% - 5% of net product revenues</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development expenses </font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$850 million - $900 million</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$925 million - $975 million</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$500 million - $525 million</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$475 million - $525 million</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Effective tax rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">17% - 18%</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">21% - 23%</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">Exelixis&#8217; 2025 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.8% for CABOMETYX effective Jan. 1, 2025.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $40.0 million of non-cash stock-based compensation.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $50.0 million of non-cash stock-based compensation.</font></div><div style="margin-bottom:9pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:5.85pt;font-weight:400;line-height:232%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:232%">Includes $80.0 million of non-cash stock-based compensation.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Third Quarter 2025 Highlights </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib Franchise Net Product Revenues and Royalties.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> Net product revenues generated by the cabozantinib franchise in the U.S. were $542.9 million during the third quarter of 2025, with net product revenues of $539.9 million from CABOMETYX (cabozantinib) and $3.1 million from COMETRIQ&#174; (cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis&#8217; collaboration partners during the quarter ended September 30, 2025, Exelixis earned $46.3 million in royalty revenues. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.192%"><tr><td style="width:1.0%"></td><td style="width:56.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Page 4 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">November&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Presented at the 2025 European Society for Medical Oncology Congress</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">ESMO 2025) and Published in </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The Lancet</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">In October, Exelixis presented detailed results from STELLAR-303 at ESMO 2025&#59; these detailed findings were simultaneously published in </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The Lancet</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">. STELLAR-303 is evaluating zanzalintinib in combination with atezolizumab (Tecentriq&#174;) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced in June, the study met one of its dual primary endpoints, with the combination of zanzalintinib and atezolizumab demonstrating a statistically significant reduction in the risk of death versus regorafenib in the intention-to-treat (ITT) population at the final analysis. An overall survival (OS) benefit with the combination was consistently observed across pre-specified subgroups, including geographic region, </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">RAS </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">status, liver involvement and prior anti-VEGF therapy. Data pertaining to the other dual primary endpoint, OS in patients without liver metastases (non-liver metastases or NLM), were immature at the data cutoff. A prespecified interim analysis showed a trend in OS favoring the combination. The trial will proceed to the planned final analysis for this endpoint. A trend for improvement in progression-free survival (PFS) with the combination was also observed in the ITT population, though statistical superiority cannot be claimed at this time due to the prespecified hierarchical testing strategy. The trend for PFS improvement with zanzalintinib in combination with atezolizumab versus regorafenib was consistent across subgroups. The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. Based on these findings, Exelixis intends to submit a New Drug Application for zanzalintinib in combination with atezolizumab for the treatment of patients with previously treated metastatic CRC in the U.S. by the end of 2025.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Presentation of Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX in Advanced Lung and Thymic Neuroendocrine Tumors (NET) at ESMO 2025. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">In October, results from a subgroup analysis of the CABINET trial evaluating CABOMETYX versus placebo in patients with previously treated advanced NET originating in the lungs or thymus were presented at ESMO 2025. These subgroup results demonstrated that CABOMETYX significantly reduced the risk of disease progression or death versus placebo in patients with lung or thymic NET. The safety profile of CABOMETYX observed in patients with lung or thymic NET was consistent with its known safety profile&#59; no new safety signals were identified. In March 2025, the U.S. Food and Drug Administration (FDA) approved CABOMETYX for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET)&#59; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET), based on results from the CABINET study. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">In August, Exelixis announced that the company had appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab oversees all aspects of the company&#8217;s drug discovery, translational research, product development and medical affairs activities. Dr. Aftab joined Exelixis in 1998, and since then has played a key role in the discovery and development of the company&#8217;s flagship medicine, CABOMETYX, which is currently the leading tyrosine kinase inhibitor in the U.S. for both the treatment of advanced renal cell carcinoma and advanced NET. During his tenure at Exelixis, Dr. Aftab has held diverse roles across the company&#8217;s research and development organizations, and most recently served as Executive Vice President, Discovery and Translational Research and Chief Scientific Officer (CSO) since December 2022. As CSO, Dr. Aftab oversaw the development of the company&#8217;s early pipeline, as well as of the translational medicine and clinical pharmacology teams supporting work streams across the spectrum of discovery research and product development. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.192%"><tr><td style="width:1.0%"></td><td style="width:56.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Page 5 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">November&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Zanzalintinib Pivotal Development Program. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">In July, Exelixis announced several updates to the zanzalintinib development program, including the initiation of the STELLAR-311 phase 3 pivotal trial in advanced NET. STELLAR-311 is evaluating zanzalintinib versus everolimus as a first oral therapy in patients with advanced NET, regardless of site of origin. The primary endpoint of the trial is PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review. The company also announced that planning is underway for the next wave of zanzalintinib pivotal trials in post-chemotherapy adjuvant CRC settings, as well as in high grade and&#47;or recurrent meningiomas.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Partner Ipsen Received Approval from the European Commission (EC) for CABOMETYX for Patients with Previously Treated Advanced NET. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">In July, Exelixis announced that its partner Ipsen received approval from the EC for CABOMETYX for adult patients with unresectable or metastatic, well-differentiated pNET and epNET who have progressed following at least one prior systemic therapy other than somatostatin analogues. This approval follows the positive opinion received from the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use in June 2025 and allows for the marketing of CABOMETYX in this indication in all 27 member states of the European Union, Norway, Liechtenstein and Iceland. In July, Ipsen also received approval for CABOMETYX as a treatment for previously treated advanced NET by health regulatory authorities in both Brazil and Australia. These approvals were based on the positive results of the phase 3 CABINET pivotal trial, which evaluated CABOMETYX compared with placebo in two cohorts of patients with previously treated NET&#58; advanced pNET and advanced epNET. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Progress of Early-stage Pipeline Programs. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">Today, Exelixis provided an update on the recent progress of its early-stage pipeline programs. In August, Exelixis initiated the phase 1 study of XB371, the company&#8217;s next-generation tissue factor-targeting antibody-drug conjugate (TF-targeting ADC) program, following U.S. FDA clearance of its Investigational New Drug application in July. Exelixis now has four ongoing phase 1 trials for its pipeline programs XL309, XB010, XB628 and XB371. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Repurchase Program. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">In August 2024, Exelixis&#8217; Board of Directors authorized a stock repurchase program (SRP) to acquire up to $500 million of the company&#8217;s common stock before December 31, 2025. In February 2025, the Board of Directors authorized the repurchase of up to an additional $500 million of the company&#8217;s common stock before December 31, 2025. Under these programs, as of September 30, 2025, Exelixis has repurchased $895.3 million of the company&#8217;s common stock, at an average price of $37.18 per share. Exelixis completed repurchases under the August 2024 SRP in the second quarter of 2025 and plans to complete repurchases under the February 2025 SRP in the fourth quarter of 2025. Since the approval of the first stock repurchase program in March 2023, the weighted-average diluted common shares outstanding has decreased from 326.3 million shares to 278.5 million shares as of September 30, 2025, and Exelixis has returned $1.9 billion to shareholders through these programs. In October, the Board of Directors authorized the repurchase of up to an additional $750 million of the company&#8217;s common stock before December 31, 2026. The October 2025 SRP will be the fifth such program to be undertaken by the company since March 2023. Stock repurchases under these programs may be made from time to time through a variety of methods, which may include open market purchases, in block trades, Rule 10b5-1 trading plans, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any stock repurchases under the stock repurchase programs will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of our common stock and general market conditions. The programs do not obligate us to acquire any amount of our common stock, and the stock repurchase programs may be modified, suspended or discontinued at any time without prior notice.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.192%"><tr><td style="width:1.0%"></td><td style="width:56.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Page 6 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">November&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%">Federal Income Tax Impact from the One Big Beautiful Bill Act.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> In July, the One Big Beautiful Bill Act was signed into law which, among other provisions, permanently repeals the requirement to capitalize domestic research and experimental (R&#38;E) expenditures for federal income tax purposes for taxable years beginning after December 31, 2024, and allows for the accelerated deduction of any remaining unamortized domestic R&#38;E expenditures. Foreign R&#38;E expenditures are still required to be capitalized and amortized ratably over 15 years. Exelixis estimates its federal cash tax benefit for previously unamortized domestic R&#38;E expenditures is $147 million with no corresponding impact to the federal income tax provision.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December&#160;31. For convenience, references in this press release as of and for the fiscal periods ended October&#160;3, 2025 and September&#160;27, 2024, are indicated as being as of and for the periods ended</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">September&#160;30, 2025 and September&#160;30, 2024.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis management will discuss the company&#8217;s financial results for the third quarter 2025 and provide a general business update during a conference call beginning at 5&#58;00&#160;p.m. ET &#47; 2&#58;00&#160;p.m. PT today, Tuesday, November&#160;4, 2025.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">To access the conference call, please register using this </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">link</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> and proceed to the Event Calendar page under the Investors &#38; News heading. A webcast replay of the conference call will also be archived on </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> for one year.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Exelixis</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX&#174; (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">, follow </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#64;ExelixisInc</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (Twitter), like </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis, Inc.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"> on Facebook and follow Exelixis on LinkedIn.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; Exelixis&#8217; plans to submit a New Drug Application for zanzalintinib in combination with atezolizumab for the treatment of patients with previously treated metastatic CRC in the U.S. by the end of 2025, which is subject to limitations on the availability of government services, such as from the FDA, as a result of the ongoing U.S. federal government shutdown&#59; Exelixis&#8217; plans to initiate additional zanzalintinib pivotal trials, including in the post-chemotherapy adjuvant CRC settings, as well as in high grade and&#47;or recurrent meningiomas, and plans for its early-stage pipeline&#59; the timing of completion for Exelixis&#8217; corporate reorganization plan by the end of fiscal year 2025&#59; Exelixis&#8217; updated financial guidance for fiscal year 2025 and any plans to provide further updates&#59; the timing, amount, and completion of any stock repurchase programs&#59; and Exelixis&#8217; scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.192%"><tr><td style="width:1.0%"></td><td style="width:56.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Page 7 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">November&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis&#8217; and its partners&#8217; ability to obtain or maintain coverage and reimbursement for these products&#59; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products&#59; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities&#59; Exelixis&#8217; ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so&#59; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and&#47;or efficacy in clinical testing&#59; uncertainties inherent in the drug discovery and product development process&#59; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved&#59; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere&#59; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements&#59; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib, zanzalintinib and other Exelixis product candidates&#59; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of its products and product candidates&#59; Exelixis&#8217; ability to protect its intellectual property rights&#59; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products&#59; changes in economic and business conditions, including as a result of changing trade policies and tariffs and the related uncertainty thereof&#59; and other factors detailed from time to time under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis&#8217; other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered trademarks of Exelixis, Inc.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">TECENTRIQ (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">-see attached financial tables-</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="i2b2b40c0a1734efb8a85df27ac801c6e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.192%"><tr><td style="width:1.0%"></td><td style="width:56.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Page 8 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">November&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:43.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">542,930&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">478,059&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1,576,227&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1,294,163&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">54,825&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">61,483&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">145,236&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">307,783&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">597,755&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">539,542&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1,721,463&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1,601,946&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">18,574&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">17,328&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">57,216&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">56,251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">199,164&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">222,570&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">611,753&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">661,406&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">123,661&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">111,801&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">395,703&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">357,800&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">51,672&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">51,672&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">19,816&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">19,816&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">33,406&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">361,215&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">403,467&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1,084,488&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1,160,535&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">236,540&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">136,075&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">636,975&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">441,411&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">15,922&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">18,709&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">51,787&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">55,861&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Other expenses, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(49)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(29)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(244)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(405)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">252,413&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">154,755&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">688,518&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">496,867&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">58,835&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">36,782&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">150,476&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">115,461&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">193,578&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">117,973&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">538,042&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">381,406&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.72&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.41&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.97&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.31&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.69&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.90&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">268,421&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">285,622&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">273,269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">291,865&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">278,535&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">291,478&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">283,701&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">296,994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="i2b2b40c0a1734efb8a85df27ac801c6e_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.192%"><tr><td style="width:1.0%"></td><td style="width:56.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">Page 9 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:700;line-height:100%">November&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">193,578&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">117,973&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">538,042&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">381,406&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - research and development</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">10,353&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">8,764&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">34,018&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">21,834&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - selling, general and administrative</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">20,532&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">14,259&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">58,868&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">45,656&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(6,569)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(5,335)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(20,917)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">(15,624)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">217,894&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">135,661&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">610,011&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">433,272&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.72&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.97&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted&#160;</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.69&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.40&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.90&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.28&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.81&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">2.23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.48&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">2.15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">1.46&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">268,421&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">285,622&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">273,269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">291,865&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">278,535&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">291,478&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">283,701&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:100%">296,994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash stock-based compensation used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>exel-20251104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:58ca7a64-f6c5-4884-ae81-544de3b20dd3,g:32284b26-19fc-4127-ab96-9bdd2ce3e58d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20251104" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20251104">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20251104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20251104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>exel-20251104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:58ca7a64-f6c5-4884-ae81-544de3b20dd3,g:32284b26-19fc-4127-ab96-9bdd2ce3e58d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_13d33317-36b1-4882-8044-e699ae79ceca_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_bd7923ba-8b17-4f3e-953f-50ef571143c9_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_759cb23c-8d80-4f45-87bb-3775dad71b50_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2bfc2256-e21a-4757-808a-ba7becb80735_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a6418ee8-bf91-452d-8827-c3303184cea7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_dfd9bffb-19bd-44e0-828c-122280a645bc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8b61cebf-5415-4576-bf6f-f679ceac53de_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8a9cb9b1-cccb-48ea-815b-1d87851677b3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_a0d9dc44-6267-4037-a281-c994f07a7212_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2ea9d69d-243d-44e5-bd31-f1b5e9ef5038_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c24b7913-a537-41e0-8475-bd03c6981a3f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8f4cb1cd-4606-4469-8de6-9bb0c94a46f1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c39f7f92-e9e1-4f60-b261-2bc3bbed679d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_05b5db8c-a3b3-4c5a-aa39-394bf648de8f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_28196c16-108d-4bbf-845b-38ec078874b7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_15520264-0af3-43aa-b80c-8a6f101dc95c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cbef59fe-4377-42eb-aa0a-4d58b41a1bd3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_576ccda3-27d5-40a6-981f-fd2a6ad5d251_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a60a29a7-40c0-479d-bbb2-cb9d5658c57e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fc30e636-e0d5-4abc-afe9-b6946a7b2280_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a728f672-a565-46fd-92f2-f44e046c3240_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_74a96989-87e2-4159-a1a4-898d341a92dc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0c194aa9-0b11-4d4a-8c2b-892667bd8ff9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>exel-20251104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:58ca7a64-f6c5-4884-ae81-544de3b20dd3,g:32284b26-19fc-4127-ab96-9bdd2ce3e58d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20251104.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_035a5a5f-4959-409f-a92f-6a1eca6f2ab0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_AmendmentFlag_035a5a5f-4959-409f-a92f-6a1eca6f2ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d8c5feb7-95ee-4d44-a8c5-9f75e04807a3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_DocumentPeriodEndDate_d8c5feb7-95ee-4d44-a8c5-9f75e04807a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5f6a8d6f-590a-45bc-ab10-4d55c6d6cae3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityRegistrantName_5f6a8d6f-590a-45bc-ab10-4d55c6d6cae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_72cd4efd-7df6-4e15-97cb-57dd3a2a0b95" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityCentralIndexKey_72cd4efd-7df6-4e15-97cb-57dd3a2a0b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4c6cadb0-c5ab-4684-9497-536c85a8d58a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityEmergingGrowthCompany_4c6cadb0-c5ab-4684-9497-536c85a8d58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_de5f60fd-a02e-4c1c-9325-f979c8ba9aa9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_Security12bTitle_de5f60fd-a02e-4c1c-9325-f979c8ba9aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4cf763d8-c334-4478-9716-58f3101e3710" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_TradingSymbol_4cf763d8-c334-4478-9716-58f3101e3710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_59e82caa-ca89-467f-be53-5eaa67005770" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_SecurityExchangeName_59e82caa-ca89-467f-be53-5eaa67005770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b6c09732-ee91-4b40-9c8b-8b830f5624ae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityFileNumber_b6c09732-ee91-4b40-9c8b-8b830f5624ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_461dff3b-d2bd-4243-82c7-912b4d4e0c9b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityIncorporationStateCountryCode_461dff3b-d2bd-4243-82c7-912b4d4e0c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2267acda-1b14-4692-aee9-7163ab618e71" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityTaxIdentificationNumber_2267acda-1b14-4692-aee9-7163ab618e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ec4330af-baeb-4bd2-a4c9-d0e787fa85f3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityAddressAddressLine1_ec4330af-baeb-4bd2-a4c9-d0e787fa85f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0f41ec83-f3d1-4642-8c50-9bfe20b060c1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityAddressCityOrTown_0f41ec83-f3d1-4642-8c50-9bfe20b060c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d09ae1c2-0754-4640-ab34-70ed9a199521" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityAddressStateOrProvince_d09ae1c2-0754-4640-ab34-70ed9a199521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0a0b9381-290a-4835-9484-c082ccc5ffa2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_EntityAddressPostalZipCode_0a0b9381-290a-4835-9484-c082ccc5ffa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ad564980-3f5e-457c-9825-3b9fa4324f44" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_CityAreaCode_ad564980-3f5e-457c-9825-3b9fa4324f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_011c0b26-4fe3-44be-a05e-5f52d8dda1e4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_LocalPhoneNumber_011c0b26-4fe3-44be-a05e-5f52d8dda1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_083b47f2-aecf-454f-8514-6b49915e7ae8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_WrittenCommunications_083b47f2-aecf-454f-8514-6b49915e7ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5bc9fbd5-7e17-4eb3-822d-971905a09a4a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_SolicitingMaterial_5bc9fbd5-7e17-4eb3-822d-971905a09a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_66832f38-e955-44e2-aff0-709d5e923b11" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_PreCommencementTenderOffer_66832f38-e955-44e2-aff0-709d5e923b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_91948b52-8a8d-4463-8f3b-1b8381c3ebb5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_91948b52-8a8d-4463-8f3b-1b8381c3ebb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6670b237-85ae-4aa1-815c-961f74937d86" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05eb4814-e269-4104-ae02-e79fcf5cdc55" xlink:to="loc_dei_DocumentType_6670b237-85ae-4aa1-815c-961f74937d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exel-20251104_g1.jpg
<TEXT>
begin 644 exel-20251104_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
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M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
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M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
MN''P#<99VIFT^2=%>\:SD,_/U6C7] KT*O,=6DC;W+^))C!A6# ](0(,5MSL
MH&60""(@\IJP;#SKZ?\ SC]3?G3_ .<?J;\Z0^!#4S?G0ON,PANH]AR#W=X0
MSHTF<I1U,"#:/MZ^%9^[L5=;_81>#>#0)O?@S,:S+/'65U&([5 TIE<&]2&_
M"D6J&=7XT/*F"8XZ*;1XSS1QGBI!]B4O-06:V/2;,V7 : 1 2S&  M)-@IMP
M,^9SSU1U!D.EB<@.!]XFF"((G/ #-C4*3-XF\YS'5@!D!4/,-7F.'EHZ$/,<
M/('<)IVY8BF:7KW;1V8X:)GRE\>4(YN@M7,CG+QB_1BI(U4VF)UDG2&_;ROB
ML-@'H*>D>TUV"UVFK@7^WRS4FU,S;HKW16<SE]/APP\UP\ZI/E&#H8@_:XV'
M*B;S*L<5CJL.<O$?5 Z$:?&E"$F=$C!6Z2^U<CEY(;[O*^$AV0?]1A^Q;\35
MC2O@F;RUJB"CK.>:/:<@:-,F&+,22<2:SYC'U@^7FF$J<0/=?HMJ/-;*!NI#
M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
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M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
ME$9/=Q2#5)$XYFC8%3VQRKE\5F]P=#[=_='D<7_K^W>(C\ R)Q/ME.M-79K%
M18\S;BA1/+1QB:CG<\[B/?C)YU"]'(LW5X=9_,J+JL=F_P#"(]W'\>@QV\^'
MX!Q<^^E]\?FY'&OZQL?B]3^ U/"3)-Q#Y"RS589JN=.V*7BYT[?X"NNIJ>E<
M:\-3RC'6$&/(IN,6>+:),D9>J2<F6NH7%+K<8&P-6RGOH*9QW&.IY1CK5->D
ML$\23P3HT<T,BAD=&&#*RG$$$' @Z#,>6*)QPMSA5-_)]P%DM%>^+O;G/-&V
M!:G)YL8]JC'T2" 0=1!V'2@X#9\N(."E.&%[J7ULB@LUHD=MK( 33DZRN,>U
M4!Y7%;X[0?9E)R.)GW8H_'#V?@I]8WSQ>FY'!S[YV?QE.R<1OU%F^SH>1DSZ
MJOGB9Y3RRNL442EY)'(5551B22=0 &ERO4,C-9*#&WY;B.SX+$QQEPYC,^+^
MENCF]&&GIX9*FIJ9%AIJ:)2\DLDA"HB*-99B0 -&N5WCCFSI?8E-VG7!A2Q=
M\E'$W0NUR.^;M!>4,[6BGW,OYKG(N,:#N:6Y$8L>@+4 %A[,-TCDG)EWJ-S+
MV;)Q\ D<X)2W,@*O:"U  4^R"])Y5R^*S>X.A]N_NCR.+_U_;O$1R:V_9EO%
M'8;+;HS+776OF2GIXE'.\DA"CH&O7I-29<I,P9Z:%MWX?;J1:>C?MI-6/"SC
MMJA';T2',66,TY7CD*J:UJ:"NA3$ZRXI96D ':0Z1YBR'F>@S39Y#NFKH90_
M5OSQS1G!XG'.KJ&[78,A<,[?.)JO*L51?,Q!3B(I:Y%AHX6',QC5W]JR]/(X
M<9=C&\]YS3:*<+['X7&[G\2J2?P'BY]]+[X_-R.+*9]SK9\H/>*ZT26I+K5Q
MTQJ%A@J%D:(2$;P4L <-F.GGGRCY4I_TM///E'RI3_I:>>?*/E2G_2T\\^4?
M*E/^EIYY\H^5*?\ 2T\\^4?*E/\ I:>>?*/E2G_2T\\^4?*E/^EIYY\H^5*?
M]+1G?C3E!40%G8W6GP &LD]UI35M',E325D23TM1&0R21R*&1U(V@@@@\F;A
M%D6X=5GK,M)O9ENT#=W9[9.",%([VHJ5Q"<Z)C)M*'18XU"H@ 51S <A;1()
MZ/(N7FBJ<^7R+%2L+'&.A@DPP$]0 1CZA,7];C;;%9*"&UV>T4T=);+=3J$B
M@@A4)'&BC8% P]&^9)S=;UN5@S!3FGKJ<G===89)8GVI)&P#HPV, =+GD7,)
M>JBC!J\M7XIN1W.W,Q6.H7F#J>XE4=Z_:*D^C#44\\E+54TJ3TE7"Q26&6)@
M\<D;C6K(P!!&PZ26',LL</$[)T$:9@B7!5N-+J2*Y0IS!SW,JC4DGL67E<5O
MCM!]F4G(X@7+/6:[7E*@N&7Z6FH*NZU,=-'-,E67:.-I" S!3B0.;3SSY1\J
M4_Z6GGGRCY4I_P!+3SSY1\J4_P"EIYY\H^5*?]+3SSY1\J4_Z6GGGRCY4I_T
MM///E'RI3_I:>>?*/E2G_2T\\^4?*E/^EIYY\H^5*?\ 2TMM_L%RI[Q9+Q3I
M5VNZTD@E@J()1O))&ZXAE8'$$<C@I]8WSQ>FY'"V]7BMAMMIM&:K7672XU#!
M(:>GAJ%:261SJ55 Q).A'_\ L^4-71=:<_\ YZ>>?*/E2G_2T\\^4?*E/^EI
MYY\H^5*?]+3SSY1\J4_Z6GGGRCY4I_TM///E'RI3_I:>>?*/E2G_ $M)[SD;
M,]MS7:J:I:DJ+A:ZA*B%)T56:)G0D!@&!([?H\1OU%F^SH>1DSZJOGB9Y463
M+74&.]YP1UJW0D/!;5.[,V(V&4^]CM;W1H !@!J '-Z!9B%51BS'4 !SG2EX
MDYJHB+E51[^4K7.N!IH)!_%NIV22J>XQ[U3CM;5RKOE>\Q[]!=H&B=QW\3[8
MY4/,T; ,.V-+MEB]Q[ERL\YAE< A9D/=13ICZF1"&'Y.;D=\5((*NIP92#B"
M"-A!U@Z)'<9PV:<N;E'?U/?3:O>:H#HE4:^A@PY-R^*S>X.A]N_NCR.+_P!?
MV[Q$<B]9KS)<(K78<OT<M==:^8@+'#"I9CVR=B@:R< -9TENEXDFMV3K=.QR
M;DK>]YI(AJ2HJ%&J2I<:V8X[F.XF &OT(LSY$S'6Y7OL> >LHGP6=%./5U,+
M!HYTU=[(I'1AI3VSC+DYW*@(V;LL+OAL!AO3VZ5]X$G63%(W:0:1-DSB'9KI
M52;H_E,E0*6N5F&.ZU)4=7,"/:\B:MKZJ&BHZ92]15U#K'%&HVL[L0 .V3I7
M9>X3U%-Q!SLP:%;K"=^R6Y]8+RU"D"I==HCA)!]4ZZ77,-_N,UWOM\JI*V[W
M2H.,L\\IQ9VPU <P U*  -0Y%LO,L EM?#NVU-[JW8:A53J:.C4'IQD=Q[3\
M!XN??2^^/S=FK?U$GN3IDWZCMWBT?(FO 6*X9ROO6461[ YU3U>[W4\H&L04
MX(>0C;J4:V&ESO\ F"Y37B^WNIDK;Q=:@XR5%1*<7<] Y@!J4  :AR+'D3*%
M)\+OM_FW(W<$PTL"8&>KJ".]BA7NFZ3@HUL-+3D7*\1:GH09KG=)% GN%=(!
MU]7/AZJ0C9C@J@*-2CDSV"H:*WYJM!>MR3F)EQ-)6[N&Y)AK,,P 251S8,.Z
M5=+OEK,5NEM&8+!5R4-YM<W?PSQ'!ACL92,&5AJ92&&H\BR9XR=7? ,PV";K
M:5FQZJ>-M4U-4*.^BF7N7'XQK TM6>,N,8#4#X/?++(P,]NKXP.OI9<.=2<5
M;8RE6&H\GBM\=H/LRD[/P8^Z-K\77D<%/K&^>+TW9<S??*N\5I/1XC?J+-]G
M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ 1,# 2(  A$! Q$!_\0
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M2W1^V&G2M<6%O*^-\D:NV.F2 3BK-5-)_P"059?]<4_]!%6Z19Y+^TO\;'^
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MM B>ZM-3FX"\<PMW*OP,>N"*_+M3E58C!Q^7>OI3]LC]I(_%KQ*_A?0+D_\
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M'PSX=T[0VN,"5K*V5&<#H"1R1[4M!ZG2W'_'K+_N'^5?B9=?\A*X_P"OEO\
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M6Y^-WQF_Y*WXY_[#=[_Z.:OU2_9]_P"2%^ _^P+:_P#HI:_*WXS?\E;\<_\
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MHR<[(4"#/K@5\SDN35<IJ3M5YH2Z6/J,\SZGG4*;E1Y:D=+WW78_'GXP?O\
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IG-W;U"DVBEHK0@3:*-HI:*5@"BBBF 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Nov. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel-20251104.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="exel-20251104.htm">exel-20251104.htm</File>
    <File>exel-20251104.xsd</File>
    <File>exel-20251104_lab.xml</File>
    <File>exel-20251104_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20251104_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exel-20251104.htm": {
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20251104",
   "dts": {
    "inline": {
     "local": [
      "exel-20251104.htm"
     ]
    },
    "schema": {
     "local": [
      "exel-20251104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20251104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20251104_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.exelixis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20251104.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20251104.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000939767-25-000127-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-25-000127-xbrl.zip
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MWP <#V1, W<"W&@)F;FIL37MZK'IQ&K2% EH0"H5I@BO \#.S6 \ 4'R50
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M9R4 52JVV8\'JJ@'G,#6Q E4<8Q%-_8L2W>_=KH/;MA67[QL?N_Y@J0>JSR
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M>[GM>HR6T& &ZJ2!P>,QGAX8+[<=%NK=%H(*O^!I=O%F:+>3OS90[3: NOU
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M1&%W.]<$3!,>:&<L GN:1U).C& L(;IVA5BAL#C0I:#[P<@1 WW](Y24B.=
M8 ^!*DC_BM?7U/RA&\Y,5X-'7UM33E)13DY42DR2D%O Z,.C\1ZHG31SQ ._
M WF@">&LY('P<@,=)+IS',6K^N=OI Z+;_. S.(_Y8C_(GVGUU!8M!_*10>+
M\>0A)@PE])_Z05%* 2&I( 5Z'X40E5&4D00A&6=1>3E99V<YE**D@BMH_3:_
MRQ_BX#_AQ_SW@;@M /M/0UW\A]EZ:!S8?Z=W7&N.\OGI9&+F4T(@\<2>Q2%
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M?RR:;-C.4CZE1C R8)H?P"H/>3A<G-?17@LCIRU?#@LQ/CW8L2$]$J+OTS>
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M(QB8O[^/6AE%7'0X@<L7PG()=]]!4C5/H9XP\#0U'U\*C+GV[2 3Q83[,K*
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M+=LQ!NYL$(_<I,J1[1U*CLYAC2-6,CI:V:)R4930A];B0.!_ZGI@^9)60$N
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MDN*JHRR!<A++!2K<1@RIP3?7.+*,FIYE1.L$#?:/MN9?'H>#B @_6*4ZATJ
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M[CJCPB>.>]QH>&5%>1;(CX'!4U1;]KA:;3.*J/&I#0 _5PDQ2J4 Z1U=I?:
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MN,,]SU'!J>DMST>!U$D]"+1R\'W8#97"*5UB]M]J;*W) 0U90)/SZ1D&Q"B
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M\I+=?Y(Z<IILCO9OCD\CQ:B,J 0(!_7.7@BX#"!(( \554GH!\1NL-RC-,V
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M&FB2T;W =9#[E(NBO"G*^I#'1<4J=5K<YE7Y<%I(M8!AJ&L28>"S1#>?@#'
MB2\ 87H_R(=2T'#PB20#]*89\UHI_.+52>BJ>9M$/).)[>S77\:AH^"+%<=I
M,AQ5%X=Q<9#;$=-C?_R)A\E!9G=GRV%O<Q\U(>*7:97I/3BNDI F2D,>QP C
MQ?68Z3. 94@XA@QR.?C_Y\^#'[LK&@VO2#R(_L'_Z6W5[6?,QV(,GR]=+%HV
M24MW3L/E<QNC!LO'8),/E<]M= V4.VM<.^=[*?7'MJJA_%*>E\6/5">Z".-(
M",D"@&(9 NRS"% "$Y!(Q"(F0XE"RR.(W4+3],J-=J,;;/5M.^2><@UMC>.+
MX-03'?P[=,)^<R-:X)[ $_>^?GN[3>_ ^I' GA>KBF7_26_JT8Q%/D.4F9-A
MA ]P3"7@G",@.)5A%!(1QI:G97;)3 SK6MO3XD[#;&>A+$%UMC\.TZ'.W2'M
M-#8>T7;8GP-HI[6]>':O'@GGJ7[XI;PL[O)%(@)?14$$E&\:*>,"L$11P".*
M(Q9S<RF#$YE/&A-C:81-"S'2CDPVZF,)I)OK<30.,NR.XJZE\1PV8OX<"'=-
M[26P8^E(_#:_SM)<P06+$4FB& &F&R' 42(!10D"B;F@"$<B0-@-P*;*Q AN
M'GA&V_N2N[;&5ITL071U/P[%P<;=<>PR-A[(5M2?@V27L;U0=BYVOXCV4K]U
M$6-&(THH(+%" ,.0 @89!H02&6#(*)*##\,V Q\9OL<K28V6_76RM?7#<+D:
MLN-IF!>G2V&;B8^Z K8.-/F%K\WTNZYW;;WN<),%@U:I6+T3X@M(,6,4^!Q"
M@"5F@ C$-0@HBF(N29(,ON-/,_"10:CG(*-EN3O6\GZ8!%='=B0,-&-W<X6.
MS-WNK= ,--VM%3K2;]U9H>OU?2@T*ZJ[R/>35]MGTO7=.D]>_1]02P,$%
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MY FN.DS-0>5%7> ;W'*4+#"10QG3[*E,PJ*L' ;:AB@(S%0FP-KHR, &:@[
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M@)E,56&X#Z?, =&JIL'KPU[0, XY-H['-*F YY(*I)(0N7$>?G!''N!1D(0
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M[E#JB;A'7W_ZH=4_.7^ONGF#^DNS?&D0J09];J@T:*Z@!NKOX0.ZAU16^E
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MJ3P8J 5;40>IU?0&Y&',36;Q?*9WGV4%ZM0SBE#I8D%XW6(6ILG#P=#A% 7
M-/"$DWAZN:'4*<0B :/5I% B3$,Q 2"A-*<H/7<F8.B$J*X(BI]C!)0:J 3#
MA.9%I/$[N!UP4Y%#9HH2=+J;\T3.5+!-9<#1[^1"-E(:1U/N#>R!LC"] I]*
M"VPQ.B="4L0T='.EMFN:5^>IRPWAC!2(YFP8>*[:MZH2G25AE$CEB*&T/A6B
M!8J9FMVF^9"1-N\08A2S2#,$)\%,9 98@IX 9<Q)/UV)<6+2?"R<L V/FW1E
MV,1$>#-#HNGRH2"BQ"K0 (A&7>%T#7OT;XNAKR"N!'Q.O)@\N3(!Y:<?NNT3
M0YD7OK/[6P^(['=V='.'.<[A>^P?]DV4"4)923J YQ7<P0"?CY0/''S33@ZB
MH52:P/>?0.,5[L7^.^8^8@YYZ-8^P6'Q0KK&C'.2<V4[V;IFF$O>,$R[X-(G
M0YW.YNFS1>G9<GDM5JZ9W53&VE[*?LK,I(,X4'G>BPF8:?[</C;ORO6H@.W_
M(90[.H-$ZKCDMUQZIJ<F332'N\BG36$'!^E@"@\E+?%<1YF/'TXM54^@G"?&
M6C&Y1*K!A79\YY><)+$;W/FJT<Y:B)O4['SFVWTU5?ET)ID6%KQPB965R[(T
M:=.KTM#3QK0FTPO55)62:>AG>91&.$.>1D=(OM$&O6T!VWD'==8'=W%%Y:%R
M<UZO=- 819<6%E%A%U!B4I08[]<(<T+1,:-*&Q</9^G<*P6<W#'7Y+2EVF+6
M>FEQZ[O1YTYI<ZEPH&?)/X\OPQB0$YM>)[!E9"C%1:&.#<)I0E!O0=C]:1AL
MI!?'DDI*JH-?R=!)IIC*ZN@ V'I9IG"0%LS0J)8E0M%D:9(6HRB9SO0VA_!3
M,:+\Q/SNLQ"9]F"8LY!.NVXON@DI=4N+M)/)4:U&5<.>4R=.<KY4DV67D7R5
M"5=EPE69<%4F7)4)=R@9454FW+I,N%Z5"7<PF7"KKV^MTCE!0MWTT&?+4*M"
M<P1L-FTH!9C# 0J2(V>D?:>%5>MUOB6;*EJK=*4VGJIZ667P*LM6];L;8P]S
MK)M1Y148\YO%IJPT5R6.9@6IM/EJ7%4?G\X7R'S8J$>K;< W<])7T[ZPRM^M
M]$ 1AM@!$6O&[R98!K[T<VNE]F^\J,8#G7ZN3=886ZTC1*BG 4*&D_VMR\E4
MP$!.AV YB+3L/2T^HF-E-DPZ%=G7I<4;@T65G<M(^7EI+BF%,I;?X6'80=F
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M;7&_ZK7"7;AL55$NT2\6R0?8BXA"YB9K+RLPS6]S@9YH%=H^.85G 5!PREY
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M2P$"% ,4    "  D@V1;9PWO9LP0  !);   $0              @ $
M97AE;"TR,#(U,3$P-"YH=&U02P$"% ,4    "  D@V1;OL6U?6,"   &!P
M$0              @ '[$   97AE;"TR,#(U,3$P-"YX<V102P$"% ,4
M"  D@V1;U=T09:JG  "'V   %               @ &-$P  97AE;"TR,#(U
M,3$P-%]G,2YJ<&=02P$"% ,4    "  D@V1;G0MM\QX*  !]50  %0
M        @ %INP  97AE;"TR,#(U,3$P-%]L86(N>&UL4$L! A0#%     @
M)(-D6\KH]W.K!@  ZC   !4              ( !NL4  &5X96PM,C R-3$Q
M,#1?<')E+GAM;%!+ 0(4 Q0    ( "2#9%N?-9VWA#<  -!/ @ :
M      "  9C,  !E>&5L,C R-3 Y,S!E>&AI8FET.3DQ+FAT;5!+!08
.!@ & (X!  !4! $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>exel-20251104_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20251104.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000939767</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock $0.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
